Charles Schwab Investment Management Inc. boosted its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 451,464 shares of the biotechnology company's stock after acquiring an additional 17,258 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.91% of Vericel worth $24,790,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in VCEL. Arcadia Investment Management Corp MI acquired a new stake in Vericel in the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC increased its stake in Vericel by 511.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock valued at $70,000 after purchasing an additional 1,058 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Vericel in the third quarter valued at approximately $92,000. Geneos Wealth Management Inc. increased its stake in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 2,240 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in Vericel in the third quarter valued at approximately $146,000.
Insider Activity at Vericel
In related news, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now directly owns 26,595 shares in the company, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jonathan Siegal sold 3,908 shares of Vericel stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92. Following the completion of the transaction, the insider now owns 1,206 shares in the company, valued at approximately $74,759.94. This trade represents a 76.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock worth $1,683,582 in the last three months. Insiders own 5.20% of the company's stock.
Vericel Price Performance
Shares of VCEL traded down $0.92 during mid-day trading on Friday, reaching $46.26. 830,229 shares of the company's stock were exchanged, compared to its average volume of 376,485. The stock has a market capitalization of $2.31 billion, a PE ratio of 771.13 and a beta of 1.78. The business's fifty day simple moving average is $54.40 and its 200-day simple moving average is $51.68. Vericel Co. has a 52-week low of $39.12 and a 52-week high of $63.00.
Wall Street Analyst Weigh In
Several equities analysts have commented on VCEL shares. Stephens reiterated an "overweight" rating and issued a $65.00 price target on shares of Vericel in a research note on Wednesday, January 15th. Canaccord Genuity Group increased their price target on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Truist Financial reiterated a "buy" rating and issued a $61.00 price target (down from $67.00) on shares of Vericel in a research note on Monday, March 3rd. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Finally, BTIG Research raised their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Vericel currently has a consensus rating of "Moderate Buy" and an average target price of $62.29.
Check Out Our Latest Stock Analysis on VCEL
Vericel Profile
(
Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Recommended Stories
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
